Plasmodium Immunotherapy for Lung Cancer

NCT ID: NCT02786589

Last Updated: 2023-06-22

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-06-27
• Study Completion Date: 2023-12-30

Brief Summary

The objective of this study is to evaluate the safety and the effectiveness of Plasmodium immunotherapy (blood-stage infection of Plasmodium vivax) for advanced non-small cell lung cancer.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.

Detailed Description

In our study，30 patients with stage III/IV NSCLC will be enrolled to receive vaccination with an optimal concentration and amount of blood-stage P. vivax to observe the infection time, rate and cycle; principal clinical symptoms such as fever and anemia; heart, liver and kidney function; changes in spleen morphology and function, and dynamic changes in the function of peripheral immune cells. Moreover, the patient's tolerance to Plasmodium infection and changes in tumor-related parameters will be observed.

The duration of the planned treatment is 3-6 months, and successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection. Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10^7 Plasmodium parasites. After vaccination, the onset and duration of peripheral parasitemia and the infection rate; principal clinical symptoms such as Chills, fever, pain (headache, joint pain, etc.), digestive tract reaction;peripheral hemogram changes；heart, liver and kidney function; changes in lung function, and dynamic changes in the function of peripheral immune cells will be observed. Moreover, the patient's tolerance to Plasmodium infection and changes in tumor-related parameters will be observed.

Conditions

Lung Cancer, Nonsmall Cell

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Blood-stage infection of P. vivax

This is a single arm study that enrolls 30 patients to receive Plasmodium immunotherapy.

Group Type: EXPERIMENTAL

Blood-stage infection of P. vivax

Intervention Type: BIOLOGICAL

Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10\^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.

Interventions

Blood-stage infection of P. vivax

Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10\^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• 18-70 years of age, male or female
• Unresectable stage III or IV non-small cell lung cancer, diagnosed by histological and radiological findings (UICC, Seventh Ed.), and of any histological subtype. Cancer staging during the initial diagnosis must be confirmed by radiographic findings (CT and/or MRI and/or PET-CT)
• During study treatment, the patient should not receive other treatments, including chemotherapy, radiotherapy, targeted therapy, other biological therapy, physical therapy, traditional Chinese medicine, and so on
• At least 5 half-life of the targeted drug (the half- life calculation is based on the targeted drug instructions) since the end the targeted therapy;More than 12 weeks since the end of radiotherapy or chemotherapy (common or continuous)
• Expected survival > 16 weeks
• ECGO score of 0 or 1
• PLT ≥100 × 10^9/L, WBC ≥ 4 × 10^9/L, and HGB ≥ 100 g/L; no significant morphological abnormalities of red blood cells, or anemia (iron deficiency anemia, autoimmune hemolytic anemia, thalassemia, etc.)
• The patient's peripheral blood immune cell count and immune function test are close to normal or normal, and the heart and lungs and kidneys are normal.
• The patient is willing to receive Plasmodium immunotherapy and is able to sign the informed consent
• For female patients: the result of a pregnancy test must be negative at screening. All subjects must consent to use birth control methods during treatment and for two months after discharge
• The subject is willing to follow the in-hospital exam and treatment and follow-up schedule
• The patient can return for regular scheduled follow-up visits during the 2-year follow-up period
• The subject agrees that the investigators may report and publish the results of this clinical study

Exclusion Criteria

• Total ≤ 4 weeks after surgical treatment or other forms of treatments
• Active chronic lung diseases (hypoxemia due to bronchial asthma, tuberculosis, other conditions); lung metastatic tumor; other comorbid tumors
• Patients with newly diagnosed brain metastasis (not including the previous brain metastatic lesion, which is not visible by image at the time of screening)
• Patients with autoimmune disease or other immunodeficiency diseases
• Patients taking long-term steroids or immunosuppressants
• Patients with severe hemoglobin disease or severe G6PD deficiency
• Patients with active or chronic symptomatic hepatitis
• Patients with other serious complications such as severe hemoptysis and massive pleural and ascitic fluid
• Liver impairment: ALT > 2.5 x ULN, AST > 2.5 x ULN, bilirubin > 1.5 x ULN
• Renal impairment: serum creatinine ≥ 1.5 x ULN
• Patients with chronic heart disease, primarily those with recent (within a year) myocardial infarction, serious arrhythmias, heart failure, or aortic aneurysm
• Patients with serious drug allergy
• Patients with splenectomy or splenomegaly
• Pregnant and nursing women
• Patients who participating in other clinical trials at the same time or less than 12 weeks since withdraw from other clinical trials
• Any condition that makes the subject ineligible to participate (in the opinion of the investigator)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CAS Lamvac Biotech Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

State Key Laboratory of Respiratory Disease

OTHER

Sponsor Role: lead

Responsible Party

Ming Ou-Yang

Associate Chief Physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ming Ou-Yang, M.D.

Role: PRINCIPAL_INVESTIGATOR

The First Affiliated Hospital, Guangzhou Medical University，China

Locations

The First Affiliated Hospital, Guangzhou Medical University

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Chengzhi Zhou, M.D.

Role: CONTACT

0086-20-83062888

Facility Contacts

Chengzhi Zhou, M.D.

Role: primary

0086-20-83062888

References

Chen L, He Z, Qin L, Li Q, Shi X, Zhao S, Chen L, Zhong N, Chen X. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS One. 2011;6(9):e24407. doi: 10.1371/journal.pone.0024407. Epub 2011 Sep 9.

Reference Type: RESULT

PMID: 21931708 (View on PubMed)

Other Identifiers

KLRD-L-001

Identifier Type: -

Identifier Source: org_study_id